ClinicalTrials.gg
CompletedNCT00293176Updated Apr 1, 2011

The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

A Phase 4 interventional study of Donepezil Hydrochloride and Placebo in Memory Loss, sponsored by Eisai Inc.. Completed at 54 sites in United States. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2011-04-01.

Sponsored by Eisai Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
821
Allocation
Randomized
Ages
45 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 225 studies in Memory Disorders with a site in United States — 35 open to participants now, 51 under way, none of them phase 3. Memory Disorders · United States.

Enrollment
3rd of 187
821 · median 68
Started
2003
with 4 others
Phase 4
10 of 225
none open now
Registered
26th of 225
by date

Among the 225 studies in Memory Disorders with a site in United States, this one is the 3rd largest by enrollment of the 187 interventional ones that give a count, is one of 5 that started in 2003, is one of 10 in phase 4, and was the 26th registered.

Memory Disorders

374 studies on the registry are indexed under Memory Disorders; 68 are open to participants now.

Browse Memory Disorders studies →

Open to participants now

35 of the 225 studies in Memory Disorders with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Memory Disorders studies recruiting now, 27 (50%) set no upper age limit and 13 (24%) stop at 75 or younger; 3 take children under 18; 22 take healthy volunteers.

This study: 45 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 225 studies in Memory Disorders with a site in United States, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.

03

Conditions studied

  • Memory Loss

Keywords

  • Cognitive impairment
  • Memory Loss
04

Who can participate

Ages eligible
45 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Memory complaint
  • Mini Mental Status Exam () score 24-28 inclusive
  • General cognition and function performance sufficiently preserved such that a diagnosis of Alzheimer's disease (AD) cannot be made
  • Generally healthy and ambulatory
  • Sufficiently fluent in English

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of probable or possible AD
  • Neurological disorders
  • History of malignant cancers
  • Previously have taken donepezil or other acetylcholinesterase (ChE) inhibitors for more than 1 month or in the past 3 months prior to study entry
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
821 participants (actual)

Study arms

  • Experimental
    1

    Drug: Donepezil Hydrochloride

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.

  • DrugPlacebo

    Subjects will receive matching placebo tablets.

06

What researchers measure

Primary outcomes

  1. Assessment of cognitive and global function in subjects with MCI.

Secondary outcomes

  1. Behavioral, global and cognitive outcomes; Neuroimaging

07

Study locations

54 sites
  • Albaster, Alabama, United States
  • Mesa, Arizona, United States
  • Peoria, Arizona, United States
  • Sun City, Arizona, United States
  • Tucson, Arizona, United States
  • Fresno, California, United States
  • Garden Grove, California, United States
  • Irvine, California, United States
  • San Francisco, California, United States
  • Denver, Colorado, United States
  • New Haven, Connecticut, United States
  • Boynton Beach, Florida, United States
  • Fort Meyers, Florida, United States
  • Hollywood, Florida, United States
  • Jacksonville, Florida, United States
  • Melbourne, Florida, United States
  • North Miami, Florida, United States
  • Ocala, Florida, United States
  • Sarasota, Florida, United States
  • St. Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Venice, Florida, United States
  • West Palm Beach, Florida, United States
  • Snellville, Georgia, United States
  • Chicago, Illinois, United States
  • Elkhart, Indiana, United States
  • New Orleans, Louisiana, United States
  • Farmington Hills, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Las Vegas, Nevada, United States
  • Kenilworth, New Jersey, United States
  • Long Branch, New Jersey, United States
  • Albany, New York, United States
  • Lexington, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Staten Island, New York, United States
  • No. Charleston, North Carolina, United States
  • Centerville, Ohio, United States
  • Cleveland, Ohio, United States
  • Toledo, Ohio, United States
  • Medford, Oregon, United States
  • Portland, Oregon, United States
  • Greensberg, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Madison, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Wichita Falls, Texas, United States
  • Salt Lake City, Utah, United States
  • Bennington, Vermont, United States
  • Charlottesville, Virginia, United States
  • Seattle, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2003, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2006
First posted
Feb 17, 2006
Start
Dec 2003
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Last update
Apr 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00293176
Lead sponsor
Eisai Inc.
Collaborators
Pfizer
First posted
Feb 17, 2006
Start date
Dec 2003
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Apr 1, 2011

Study contacts

Anita Murthy
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion